In the second episode of this three-part series, Dr. Stacey Clardy and Dr. Mary Schroth discuss the currently available treatments for spinal muscular atrophy. Show reference: https://www.neurology.org/doi/full/10.1212/CPJ.0000000000200310
In the first episode of this three-part series, Dr. Stacey Clardy and Dr. Mary Schroth discuss the most common types of spinal muscular atrophy. Show reference: https://www.neurology.org/doi/full/10.1212/CPJ.0000000000200310
In part two of this series, Dr. Gregg Day and Dr. Sebastian Palmqvist discuss how this new blood test can enhance the accuracy of diagnosing Alzheimer’s disease in patients with cognitive symptoms. Show reference: https://jamanetwork.com/journals/jama/fullarticle/2821669
In the second part of this two-part series, Dr. Jeff Ratliff and Dr. Calum Hamilton discuss the clinical criteria that listeners should look out for, indicating a subtype of mild cognitive impairment known as DLB, which could potentially progress into a full dementia with Lewy body phenotype. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499
In part one of this two-part series, Dr. Gregg Day and Dr. Sebastian Palmqvist discuss the top-line findings from the study exploring the diagnostic performance of blood biomarkers for Alzheimer disease in clinical cohorts. Show reference: https://jamanetwork.com/journals/jama/fullarticle/2821669
In part one of this two-part series, Dr. Jeff Ratliff and Dr. Calium discuss the risk of developing dementia among patients with MCI at three or five-year time points. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499
Dr. Jeff Ratliff talks about the FDA approval of Crexont for the treatment of Parkinson disease. Show reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2808496
Dr. Jeff Ratliff discusses an exciting study in the world of deep brain stimulation for Parkinson disease. Show reference: https://www.nature.com/articles/s41591-024-03196-z
Dr. Tesha Monteith talks about the efficacy of atogepant for the preventive treatment of chronic migraine in participants with and without acute medication overuse. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209584
Dr. Stacey Clardy and Dr. Nicola de Souza discuss how to improve care in the clinic for these veterans and military service members. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209417
In the first installment of this two-part series, Dr. Jeff Ratliff and Dr. Daniel Weintraub discuss the risks associated with the development of dementia in patients diagnosed with Parkinson disease. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209699
In part two of this two-part series, Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss why clinicians should be cautious when relying too much on dopaminergic imaging. Show reference: https://doi.org/10.1212/WNL.0000000000209453
In part two of this two-part series, Dr. Tesha Monteith discusses the key features of long COVID. Show reference: https://doi.org/10.17226/27768
In part one of this two-part series, Dr. Tesha Monteith discusses the 2024 National Academies of Sciences, Engineering, and Medicine formal definition of long COVID. Show reference: https://doi.org/10.17226/27768
Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss the strengths of dopamine transporter imaging or DAT imaging in diagnosing patients with Parkinsonian disorders. Show references: https://doi.org/10.1212/WNL.0000000000209453
Dr. Dan Ackerman and Dr. Luciano A. Sposato discuss the topic of embolic stroke of undetermined sources and the controversies surrounding cardiac monitoring and anticoagulation. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209535
Dr. Tesha Monteith provides an overview of the updated position statement on migraine prevention by the American Headache Society.
In part two of this two-part series, Dr. Dan Ackerman and Dr. Gaspard Gerschenfeld discuss the differences in treatment between American Stroke Centers and those in France. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209398
Dr. Meagan Seay discusses a relatively recently described but very interesting phenomenon called transient smartphone blindness. This is a phenomenon causing acute, painless, transient, monocular vision loss associated with smartphone use while lying down in the dark. Show reference: Transient Smartphone Blindness - EyeWiki
Dr. Dan Ackerman and Dr. Gaspard Gerschenfeld discuss the efficacy and safety of both thrombolytics in patients with large ischemic core. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209398
Dr. Jason Crowell and Dr. Colin Hoy discuss the concept of prodromal Parkinson disease and the ethical considerations surrounding its diagnosis. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209522
In the last episode of this three-part series, Dr. Jeff Ratliff discusses how to approach patients presenting with emergent rigidity and difficulty moving.
In the second episode of this three-part series, Dr. Jeff Ratliff provides a rapid overview of hyperkinetic disorders that require urgent attention.
In the first episode of this three-part series, Dr. Jeff Ratliff discusses a few key points to help recognize and initiate treatment for patients with movement disorder emergencies, focusing on the initial approach to these disorders. It is important to consider medications, labs, and imaging as part of the evaluation process.
Dr. Halley Alexander and Dr. Kimford Meador discuss perinatal exposure to anti-seizure medications and its effects on creativity and executive function in children. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209448
Dr. Matthew Barrett and Dr. Michael S. Okun discuss the caution and deliberation needed in understanding Parkinson disease biomarkers. Show reference: https://jamanetwork.com/journals/jamaneurology/article-abstract/2820441
In the final episode of this two-part series, Dr. Joe Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized myasthenia gravis. In this episode, he will talk about two of the treatment medications: Ravulizumab + zilucoplan. Show references: https://doi.org/10.1016/s1474-4422(21)00159-9 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00077-7/abstract...
In the final part of this two-part series, Dr. Andy Southerland and Dr. Lidia Moura discuss strategies on how clinicians can mitigate bias when using large language models. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209497
Dr. Justin Abbatemarco, Dr. Michael R. Wilson, and Dr. John Pluvinage discuss their discovery of anti-CD320 antibodies in patients with neurologic manifestations of B12 deficiency and discuss the potential implications for diagnosis and treatment. Show reference: https://www.science.org/doi/10.1126/scitranslmed.adl3758
In part one of the part-two series, Dr. Andy Southerland and Dr. Lidia Moura discuss the major findings related to large language models (LLMs) for neurologic care. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209497
